secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2025-03-14T23:59:59+00:00
Accession:  0001829126-25-001770
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel acquires Plogosertib assets from liquidated subsidiary for £250K
-------------------------------------------------------------------------

- Cyclacel Pharmaceuticals buys PLK1 inhibitor Plogosertib assets from wholly-owned UK subsidiary in liquidation for £250,000.
- Includes patent rights, API, CMC data, preclinical and clinical data, and know-how related to Plogosertib.
- Buyer agrees to only sell assets for cash consideration within 24 months; any surplus (50% of net proceeds) paid to subsidiary.
- Transaction closed on March 10, 2025; Patent Assignment Agreement also executed.
- Debt/liabilities of seller not assumed; buyer responsible for subsequent disposal surplus payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000182912625001770/0001829126-25-001770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000182912625001770/cyclacel_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-001770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer